Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DX5JNH
|
||||
Drug Name |
[4-(2,4-Difluoro-5-methoxycarbamoyl-phenylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid 3-piperidin-1-yl-propyl ester
|
||||
Synonyms |
CHEMBL192318
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C26H33F2N7O4
|
||||
Canonical SMILES |
CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCCCN4CCCCC4)c(C(C)C)c23)c(F)cc1F
|
||||
InChI |
InChI=1S/C26H33F2N7O4/c1-16(2)22-21(32-26(37)39-11-7-10-34-8-5-4-6-9-34)14-35-23(22)24(29-15-30-35)31-20-12-17(25(36)33-38-3)18(27)13-19(20)28/h12-16H,4-11H2,1-3H3,(H,32,37)(H,33,36)(H,29,30,31)
|
||||
InChIKey |
LMHPBVGQEGWFGF-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
HIF-1 signaling pathway | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
S1P3 pathway | |||||
VEGFR1 specific signals | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.